April 17 (Reuters) - Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday. (Reporting by Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
775 USD | -0.36% | -0.23% | +32.95% |
05-08 | China Merchants Initiates Eli Lilly at Buy Rating With $852 Price Target | MT |
05-07 | Coca Cola's new bond prices tight, investors still hungry for new debt | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.94% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B | |
-1.81% | 160B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients